Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

Peroxisome proliferator-activated receptor (PPAR) α, β/δ, and γ modulate lipid homeostasis.
PPARα regulates lipid metabolism in the liver, the organ that largely controls whole-body …

Aims To conduct a systematic literature review to identify recent epidemiological, biomarker,
genetic and clinical evidence that expands our understanding of nonalcoholic fatty liver …

Introduction Semaglutide, a peptidic GLP-1 receptor agonist, has been clinically approved
for treatment of type 2 diabetes mellitus and is available in subcutaneous and oral dosage …

Nonalcoholic Fatty Liver Disease (NAFLD) represents the leading cause of liver disease in
developed countries but its diffusion is currently also emerging in Asian countries, in South …

To investigate the pathogenesis of a congenital form of hepatic fibrosis, human hepatic
organoids were engineered to express the most common causative mutation for Autosomal …

Systemic rheumatic diseases (SRDs) are chronic, inflammatory, autoimmune disorders with
the presence of autoantibodies that may affect any organ or system. Liver dysfunction in …

Background Babaodan (BBD), a traditional Chinese medicine, has been shown to have
protective effects during liver injury and ameliorate liver disease progression, but little is …

Increasing studies have identified the potential of mesenchymal stem cell-derived
extracellular vesicles (MSC-EVs) in non-alcoholic fatty liver disease (NAFLD) treatment …

Resmetirom, a liver-directed, orally active agonist of THR-β, could play a favorable role in
treating NASH, but little is known about the underlying mechanism. A NASH cell model was …